Physician profile
Michael R Odonnell
NPI 1629173919
$495.76
in general payments reported to CMS, 2019-2025
12 companies · $345 in 2025
The $345 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.55 · 2021: $15.69 · 2022: $20.58 · 2023: $22.76 · 2024: $38.28 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $131.64 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Sanofi Pasteur INC. | $119.13 | 2025 | |
| Alk-Abello, INC | $47.93 | 2025 | Neffy |
| Seqirus USA INC | $47.93 | 2025 | Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $28.37 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $23.59 | 2025 | Jornay Pm |
| Pfizer INC. | $22.36 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.26 | 2025 | |
| Cranial Technologies, INC | $13.84 | 2019 | |
| Kaleo, INC. | $13.59 | 2019 | |
| Phadia US INC. | $13.58 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Odonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.